Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

The Lancet Diabetes and Endocrinology

Volumn 6, Issue 2, 2018, Pages 105-113

  Bethel, M Angelyn ^a   Patel, Rishi A ^a   Merrill, Peter ^b   Lokhnygina, Yuliya ^b   Buse, John B ^c   Mentz, Robert J ^b   Pagidipati, Neha J ^b   Chan, Juliana C ^d   Gustavson, Stephanie M ^e   Iqbal, Nayyar ^e   Maggioni, Aldo P ^f   Öhman, Peter ^e   Poulter, Neil R ^g   Ramachandran, Ambady ^h,i   Zinman, Bernard ^j,k   Hernandez, Adrian F ^b   Holman, Rury R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e ASTRAZENECA   (United Kingdom)

^f ANMCO RESEARCH CENTER   (Italy)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h India Diabetes Research Foundation   (India)

ⁱ Dr A Ramachandran's Diabetes Hospitals   (India)

^j MOUNT SINAI HOSPITAL   (Canada)

^k UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; LIXISENATIDE; SEMAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; DIABETIC PATIENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATALITY; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; HYPOGLYCEMIA; MAJOR ADVERSE CARDIAC EVENT; META ANALYSIS; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PANCREATITIS; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; THYROID MEDULLARY CARCINOMA; UNSTABLE ANGINA PECTORIS; AGONISTS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DRUG EFFECT; MORTALITY; PROGNOSIS; SURVIVAL RATE;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; PROGNOSIS; SURVIVAL RATE;

EID: 85044600598     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30412-6     Document Type: Article

References (18)

1. Nauck, M, Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 18 (2016), 203–216.
2. Nauck, MA, Meier, JJ, Cavender, MA, Abd El Aziz, M, Drucker, DJ, Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136 (2017), 849–870.
3. Pfeffer, MA, Claggett, B, Diaz, R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
4. Marso, SP, Daniels, GH, Brown-Frandsen, K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
5. Marso, SP, Bain, SC, Consoli, A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
6. Holman, RR, Bethel, MA, Mentz, RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377 (2017), 1228–1239.
7. Jadad, AR, Moore, RA, Carroll, D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996), 1–12.
8. 2 index?. Psychol Methods 11 (2006), 193–206.
9. US Food and Drug Administration. FDA briefing document. Endocrinologic and Metabolic Drugs Advisory Committee meeting (EMDAC). https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM563334.pdf, June 20, 2017 (accessed Sept 20, 2017).
10. US National Library of Medicine. Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (Lixisenatide) (ELIXA) study results. https://clinicaltrials.gov/ct2/show/results/NCT01147250 (accessed Sept 20, 2017).
11. Novo Nordisk. Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results. http://www.novonordisk-trials.com/Website/pdf/registry/ex22113748.pdf (accessed Sept 20, 2017).
12. Rosenstock, J, Raccah, D, Korányi, L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 36 (2013), 2945–2951.
13. Buse, JB, Drucker, DJ, Taylor, KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33 (2010), 1255–1261.
14. Buse, JB, Nauck, M, Forst, T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381 (2013), 117–124.
15. Hramiak, I, Ahmann, A, Capethorn, M, et al. Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3). Can J Diabetes, 40(suppl), 2016, S41.
16. Nauck, MA, Friedrich, N, Do GLP-1-based therapies increase cancer risk?. Diabetes Care 36:suppl 2 (2013), S245–S252.
17. Gier, B, Butler, PC, Lai, CK, Kirakossian, D, DeNicola, MM, Yeh, MW, Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab 97 (2012), 121–131.
18. Waser, B, Beetschen, K, Pellegata, NS, Reubi, JC, Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuroendocrinology 94 (2011), 291–301.